Report cover image

Global Psoriasis Biosimilar Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 195 Pages
SKU # APRC20279072

Description

Summary

According to APO Research, the global Psoriasis Biosimilar market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Psoriasis Biosimilar market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Psoriasis Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Psoriasis Biosimilar market include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Psoriasis Biosimilar, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Psoriasis Biosimilar, also provides the value of main regions and countries. Of the upcoming market potential for Psoriasis Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Psoriasis Biosimilar revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Psoriasis Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Psoriasis Biosimilar company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Psoriasis Biosimilar Segment by Company


Amgen Inc

Celltrion

Coherus BioSciences

Fresenius Kabi

GenScript

Gyros Protein Technologies AB

Hoffmann-La Roche Ltd

Novartis International AG

Reddy's Laboratories

Samsung Bioepis

Samsung Bioepis Co., Ltd.

Viatris

Pfizer Inc.

Merck KGaA

Sandoz

Psoriasis Biosimilar Segment by Type


TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)

Other Biosimilars

Psoriasis Biosimilar Segment by Application


Plaque Psoriasis

Psoriatic Arthritis

Other

Psoriasis Biosimilar Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Psoriasis Biosimilar status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Psoriasis Biosimilar key companies, revenue, market share, and recent developments.
3. To split the Psoriasis Biosimilar breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Psoriasis Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Psoriasis Biosimilar significant trends, drivers, influence factors in global and regions.
6. To analyze Psoriasis Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psoriasis Biosimilar industry.
Chapter 3: Detailed analysis of Psoriasis Biosimilar company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Psoriasis Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Psoriasis Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Psoriasis Biosimilar Market Size, 2020 VS 2024 VS 2031
1.3 Global Psoriasis Biosimilar Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Psoriasis Biosimilar Market Dynamics
2.1 Psoriasis Biosimilar Industry Trends
2.2 Psoriasis Biosimilar Industry Drivers
2.3 Psoriasis Biosimilar Industry Opportunities and Challenges
2.4 Psoriasis Biosimilar Industry Restraints
3 Psoriasis Biosimilar Market by Company
3.1 Global Psoriasis Biosimilar Company Revenue Ranking in 2024
3.2 Global Psoriasis Biosimilar Revenue by Company (2020-2025)
3.3 Global Psoriasis Biosimilar Company Ranking (2023-2025)
3.4 Global Psoriasis Biosimilar Company Manufacturing Base and Headquarters
3.5 Global Psoriasis Biosimilar Company Product Type and Application
3.6 Global Psoriasis Biosimilar Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Psoriasis Biosimilar Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Psoriasis Biosimilar Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Psoriasis Biosimilar Market by Type
4.1 Psoriasis Biosimilar Type Introduction
4.1.1 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
4.1.2 Other Biosimilars
4.2 Global Psoriasis Biosimilar Sales Value by Type
4.2.1 Global Psoriasis Biosimilar Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Psoriasis Biosimilar Sales Value by Type (2020-2031)
4.2.3 Global Psoriasis Biosimilar Sales Value Share by Type (2020-2031)
5 Psoriasis Biosimilar Market by Application
5.1 Psoriasis Biosimilar Application Introduction
5.1.1 Plaque Psoriasis
5.1.2 Psoriatic Arthritis
5.1.3 Other
5.2 Global Psoriasis Biosimilar Sales Value by Application
5.2.1 Global Psoriasis Biosimilar Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Psoriasis Biosimilar Sales Value by Application (2020-2031)
5.2.3 Global Psoriasis Biosimilar Sales Value Share by Application (2020-2031)
6 Psoriasis Biosimilar Regional Value Analysis
6.1 Global Psoriasis Biosimilar Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Psoriasis Biosimilar Sales Value by Region (2020-2031)
6.2.1 Global Psoriasis Biosimilar Sales Value by Region: 2020-2025
6.2.2 Global Psoriasis Biosimilar Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Psoriasis Biosimilar Sales Value (2020-2031)
6.3.2 North America Psoriasis Biosimilar Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Psoriasis Biosimilar Sales Value (2020-2031)
6.4.2 Europe Psoriasis Biosimilar Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Psoriasis Biosimilar Sales Value (2020-2031)
6.5.2 Asia-Pacific Psoriasis Biosimilar Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Psoriasis Biosimilar Sales Value (2020-2031)
6.6.2 South America Psoriasis Biosimilar Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Psoriasis Biosimilar Sales Value (2020-2031)
6.7.2 Middle East & Africa Psoriasis Biosimilar Sales Value Share by Country, 2024 VS 2031
7 Psoriasis Biosimilar Country-level Value Analysis
7.1 Global Psoriasis Biosimilar Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Psoriasis Biosimilar Sales Value by Country (2020-2031)
7.2.1 Global Psoriasis Biosimilar Sales Value by Country (2020-2025)
7.2.2 Global Psoriasis Biosimilar Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.3.2 USA Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.4.2 Canada Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.6.2 Germany Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.7.2 France Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.7.3 France Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.9.2 Italy Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.10.2 Spain Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.11.2 Russia Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.14.2 China Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.14.3 China Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.15.2 Japan Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.17.2 India Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.17.3 India Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.18.2 Australia Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.22.2 Chile Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.24.2 Peru Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.26.2 Israel Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.27.2 UAE Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.29.2 Iran Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Psoriasis Biosimilar Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Psoriasis Biosimilar Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Psoriasis Biosimilar Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Amgen Inc
8.1.1 Amgen Inc Comapny Information
8.1.2 Amgen Inc Business Overview
8.1.3 Amgen Inc Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
8.1.5 Amgen Inc Recent Developments
8.2 Celltrion
8.2.1 Celltrion Comapny Information
8.2.2 Celltrion Business Overview
8.2.3 Celltrion Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
8.2.5 Celltrion Recent Developments
8.3 Coherus BioSciences
8.3.1 Coherus BioSciences Comapny Information
8.3.2 Coherus BioSciences Business Overview
8.3.3 Coherus BioSciences Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
8.3.5 Coherus BioSciences Recent Developments
8.4 Fresenius Kabi
8.4.1 Fresenius Kabi Comapny Information
8.4.2 Fresenius Kabi Business Overview
8.4.3 Fresenius Kabi Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
8.4.5 Fresenius Kabi Recent Developments
8.5 GenScript
8.5.1 GenScript Comapny Information
8.5.2 GenScript Business Overview
8.5.3 GenScript Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.5.4 GenScript Psoriasis Biosimilar Product Portfolio
8.5.5 GenScript Recent Developments
8.6 Gyros Protein Technologies AB
8.6.1 Gyros Protein Technologies AB Comapny Information
8.6.2 Gyros Protein Technologies AB Business Overview
8.6.3 Gyros Protein Technologies AB Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
8.6.5 Gyros Protein Technologies AB Recent Developments
8.7 Hoffmann-La Roche Ltd
8.7.1 Hoffmann-La Roche Ltd Comapny Information
8.7.2 Hoffmann-La Roche Ltd Business Overview
8.7.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
8.7.5 Hoffmann-La Roche Ltd Recent Developments
8.8 Novartis International AG
8.8.1 Novartis International AG Comapny Information
8.8.2 Novartis International AG Business Overview
8.8.3 Novartis International AG Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
8.8.5 Novartis International AG Recent Developments
8.9 Reddy's Laboratories
8.9.1 Reddy's Laboratories Comapny Information
8.9.2 Reddy's Laboratories Business Overview
8.9.3 Reddy's Laboratories Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
8.9.5 Reddy's Laboratories Recent Developments
8.10 Samsung Bioepis
8.10.1 Samsung Bioepis Comapny Information
8.10.2 Samsung Bioepis Business Overview
8.10.3 Samsung Bioepis Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
8.10.5 Samsung Bioepis Recent Developments
8.11 Samsung Bioepis Co., Ltd.
8.11.1 Samsung Bioepis Co., Ltd. Comapny Information
8.11.2 Samsung Bioepis Co., Ltd. Business Overview
8.11.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
8.11.5 Samsung Bioepis Co., Ltd. Recent Developments
8.12 Viatris
8.12.1 Viatris Comapny Information
8.12.2 Viatris Business Overview
8.12.3 Viatris Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.12.4 Viatris Psoriasis Biosimilar Product Portfolio
8.12.5 Viatris Recent Developments
8.13 Pfizer Inc.
8.13.1 Pfizer Inc. Comapny Information
8.13.2 Pfizer Inc. Business Overview
8.13.3 Pfizer Inc. Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
8.13.5 Pfizer Inc. Recent Developments
8.14 Merck KGaA
8.14.1 Merck KGaA Comapny Information
8.14.2 Merck KGaA Business Overview
8.14.3 Merck KGaA Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
8.14.5 Merck KGaA Recent Developments
8.15 Sandoz
8.15.1 Sandoz Comapny Information
8.15.2 Sandoz Business Overview
8.15.3 Sandoz Psoriasis Biosimilar Revenue and Gross Margin (2020-2025)
8.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
8.15.5 Sandoz Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.